Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2018

View Archived Issues

siRNA prevents pre-eclampsia in mice and primates

Anti-Andean antibodies protect postexposure

Imiquimod analogue fights more strains of Leishmania

Lung specificity means low tox for inhalable JAK inhibitor

Presepsin is a prognostic marker in congenital heart disease

Phase I results for PIN-201104 support progression to phase II for asthma

First dosing in phase Ib study of EDP-1815 in psoriasis and atopic dermatitis

miR-21 predicts functional worsening in children with CHD-associated pulmonary hypertension

European Commission approves Poteligeo for mycosis fungoides and Sezary syndrome

FDA grants accelerated approval to Vitrakvi for advanced solid tumors with NTRK gene fusion

HBV capsid assembly inhibitors discovered at Shanghai Longwood Biopharmaceuticals

Sanford Burnham Prebys Medical Discovery Institute identifies ACP1 inhibitors

REVOLUTION Medicines synthesizes rapamycin analogues

Cyclin-dependent kinase inhibitors patented by Selection Bioscience

Gene methylation of nontumoral liver tissue predicts recurrence of HCC after surgical resection

BAT-8001, a potent anti-HER2 antibody-drug conjugate, shows promising preclinical profile

Phase I study demonstrates bioequivalence of CT-P16 with the reference bevacizumab products

Aurigene presents AU-15330, a novel dual degrader of SMARCA2/4

G1 Therapeutics reports topline data from second phase II trial of trilaciclib in first-line SCLC

Belgian clearances for phase I trial of anti-IL-7 receptor antagonist OSE-127

Janssen initiates phase I study of live biotherapeutic product VE-202 for IBD

European Commission approves pegfilgrastim biosimilar Ziextenzo

FDA clears IND for phase I trial of AVID-200 in solid tumors

Vivace Therapeutics identifies YAP1/TEAD interaction inhibitors

New BTK inhibitors developed at the Korea Research Institute of Chemical Technology

Cortexyme patents gingipain R1/R2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...